Malecare Advanced Prostate Cancer Teleconference
Join us for a conversation about treating advanced stage prostate cancer, with James M. McKiernan, M.D. and Joel Nowak, M.A., M.S.W. […]
Medicare/ Trailblazer Rejects Reimbursement for Provenge & Jevtana!
A member of the advanced prostate cancer on-line support group who is the wife of an advanced prostate cancer survivor in New Mexico just informed us that Trailblazer (the MAC that controls New Mexico reimbursements for Medicare and Medicaid) has said they will not pay for her husband to get Provenge. They were also told [...]
Salvage Radiotherapy after High-Intensity Focused Ultrasound (HIFU) for Recurrent Localized Prostate Cancer
HIFU has been a common primary prostate cancer treatment in Europe for quite a while. Currently, in the United States, there are a number of clinical trial sites evaluating HIFU as a primary treatment. Like all other primary treatments there is a significant failure rate causing men to move on to salvage therapy. In Europe [...]
Phase II Study of Nitric Oxide for Men with Increasing PSAs After Primary Treatment for Prostate Cancer
Biochemical recurrence of prostate cancer after primary therapy (PSA only) remains a significant problem. Deciding on the best treatment options for men who have failed primary therapy without documented evidence of metastatic disease remains limited and controversial. Androgen deprivation therapy (ADT), the usual next step for biochemical recurrence does prolong the time to further disease [...]
Can B7-H3 Expression Serve as a Biomarker of Biochemical Recurrence after Salvage Radiation Therapy for Recurrent Prostate Cancer?
Current knowledge makes it very difficult to predict which men will experience biochemical recurrence (BCR) after salvage radiation therapy (SRT) for recurrent prostate cancer (PCa). We are also lacking in novel targets for adjuvant therapies. At the College of Medicine, Mayo Clinic Florida, Jacksonville, FL., researchers evaluated the association of B7-H3 expression in primary PCa [...]